Reduced-Intensity Allogeneic Stem Cell Transplantation for Children With Neuroblastoma Who Failed Tandem Autologous Stem Cell Transplantation

被引:16
|
作者
Sung, Ki Woong [1 ]
Park, Jun Eun [2 ]
Chueh, Hee Won [1 ]
Lee, Soo Hyun [1 ]
Yoo, Keon Hee [1 ]
Koo, Hong Hoe [1 ]
Kim, Ju Youn [1 ]
Cho, Eun Joo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul 135710, South Korea
[2] Ajou Univ, Sch Med, Dept Pediat, Suwon 441749, South Korea
关键词
allogeneic stem cell transplantation; graft-versus-tumor effect; haploidentical stem cell transplantation; neuroblastoma; reduced-intensity conditioning; BONE-MARROW-TRANSPLANTATION; HIGH-RISK NEUROBLASTOMA; HIGH-DOSE THERAPY; MYELOABLATIVE CHEMOTHERAPY; REFRACTORY NEUROBLASTOMA; GRAFT; RESCUE; RECURRENT; IODINE-131-METAIODOBENZYLGUANIDINE; CONSOLIDATION;
D O I
10.1002/pbc.23035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. To date, no effective curative option is available for children with neuroblastoma (NB) who failed tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). The present study evaluated the feasibility and efficacy of reduced-intensity allogeneic stem cell transplantation (RI alloSCT) in six children with NB who failed tandem HDCT/autoSCT. Procedure. A cyclophosphamide/fludarabine regimen was used as a conditioning for HLA-matched SCT, and ATG was added for haploidentical SCT. Peripheral blood stem cells from four HLA-matched donors and two haploidentical donors were transplanted. Immune suppression was rapidly tapered if graft-versus-host disease (GVHD) was absent. Results. Regimen-related short-term toxicity was manageable, and complete donor chimerism was achieved in the early period after transplant. Grade I/II acute GVHD developed or was induced in all patients. Tumor response, attributed to a graft-versus-tumor (GVT) effect, was observed in two of six patients after induction of acute GVHD. The other four patients with significant tumor burden prior to transplant had tumor progression despite presence of GVHD. However, it was difficult to effectively reduce the tumor burden prior to transplant through the use of conventional treatment modalities. Conclusion. Although regimen-related short-term toxicity was manageable in intensively pretreated patients with NB, GVT effect was not sufficiently strong to control tumor progression in patients who had a significant tumor burden at transplant. Therefore, new treatment modalities to effectively reduce tumor burden prior to transplant in concert with post-transplant adjuvant treatment to enhance the GVT effect are needed to improve the outcome after RI alloSCT. Pediatr Blood Cancer 2011;57:660-665. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 50 条
  • [41] The "cytokine storm" at the era of reduced-intensity conditioning allogeneic stem cell transplantation
    Mohty, M
    Gaugler, B
    Faucher, C
    Vey, N
    Stoppa, AM
    Coso, D
    Viens, P
    Gastaut, JA
    Olive, D
    Blaise, D
    BONE MARROW TRANSPLANTATION, 2005, 35 : S79 - S80
  • [42] Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Kikuchi, Taku
    Mori, Takehiko
    Koda, Yuya
    Kohashi, Sumiko
    Kato, Jun
    Toyama, Takaaki
    Nakazato, Tomonori
    Aisa, Yoshinobu
    Shimizu, Takayuki
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (06) : 670 - 677
  • [43] Cytomegalovirus infections following reduced-intensity allogeneic stem cell transplantation.
    Nakamura, R
    Cohen, S
    Palmer, J
    Hawkins, G
    Tegtmeier, B
    Spielberger, R
    Smith, E
    Ito, J
    O'Donnell, MR
    Smith, D
    Zaia, JA
    Forman, SJ
    BLOOD, 2004, 104 (11) : 617A - 617A
  • [44] Reduced-intensity stem cell transplantation in children and adolescents:: The Mexican experience
    Gómez-Almaguer, D
    Ruiz-Argüelles, GJ
    Tarín-Arzaga, LD
    González-Llano, O
    Jaime-Pérez, JC
    López-Martínez, B
    Cantú-Rodríguez, OG
    Herrera-Garza, JL
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (03) : 157 - 161
  • [45] Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
    Chen, Yi-Bin
    Li, Shuli
    Fisher, David C.
    Driscoll, Jessica
    Del Rio, Candice
    Abramson, Jeremy
    Armand, Philippe
    Barnes, Jeffrey
    Brown, Jennifer
    Cutler, Corey
    El-Jawahri, Areej
    Ho, Vincent T.
    Hochberg, Ephraim
    McAfee, Steven
    Takvorian, Ronald
    Spitzer, Thomas R.
    Antin, Joseph H.
    Soiffer, Robert
    Jacobsen, Eric
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (09) : 1583 - 1588
  • [46] A MULTICENTER COMPARISON OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWED BY REDUCED-INTENSITY ALL STEM CELL TRANSPLANTATION WITH TANDEM AUTOLOGOU STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA :THE KOREAN MULTIPLE MYEOMA WORKING PARTY (KMMWP)
    Min, C. K.
    Kim, H.
    Kim, K.
    Kwak, J. Y.
    Lee, S. T.
    Won, J. H.
    Yoon, S. S.
    Lee, J. H.
    Suh, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 85 - 85
  • [47] Autologous stem cell transplantation for the treatment of children neuroblastoma
    Hedayati-Asl, A. A.
    Tashvighi, M.
    Mehrvar, A.
    Fallah, V.
    Zangooei, R.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S311 - S311
  • [48] Late effects after autologous peripheral blood stem cell transplantation followed by reduced-intensity allogeneic peripheral blood stem cell transplantation in patients with multiple myeloma
    Zinke-Cerwenka, W
    Eibl, M
    Neumeister, P
    Sill, H
    Linkesch, W
    BONE MARROW TRANSPLANTATION, 2006, 37 : S113 - S113
  • [49] Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC
    Tessoulin, B.
    Ceballos, P.
    Chevallier, P.
    Blaise, D.
    Tournilhac, O.
    Gauthier, J.
    Maillard, N.
    Tabrizi, R.
    Choquet, S.
    Carras, S.
    Ifrah, N.
    Guillerm, G.
    Mohty, M.
    Tilly, H.
    Socie, G.
    Cornillon, J.
    Hermine, O.
    Daguindau, E.
    Bachy, E.
    Girault, S.
    Marchand, T.
    Oberic, L.
    Reman, O.
    Leux, C.
    Le Gouill, S.
    BONE MARROW TRANSPLANTATION, 2016, 51 (09) : 1184 - 1190
  • [50] Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC
    B Tessoulin
    P Ceballos
    P Chevallier
    D Blaise
    O Tournilhac
    J Gauthier
    N Maillard
    R Tabrizi
    S Choquet
    S Carras
    N Ifrah
    G Guillerm
    M Mohty
    H Tilly
    G Socie
    J Cornillon
    O Hermine
    É Daguindau
    E Bachy
    S Girault
    T Marchand
    L Oberic
    O Reman
    C Leux
    S Le Gouill
    Bone Marrow Transplantation, 2016, 51 : 1184 - 1190